Literature DB >> 30026001

PARP inhibitors and quality of life in ovarian cancer.

Daisuke Aoki1, Tatsuyuki Chiyoda2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30026001     DOI： 10.1016/S1470-2045(18)30435-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Multiple Components of Protein Homeostasis Pathway Can Be Targeted to Produce Drug Synergies with VCP Inhibitors in Ovarian Cancer.

Authors:  Prabhakar Bastola; Gary S Leiserowitz; Jeremy Chien
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

2.  Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data.

Authors:  Shalkar Adambekov; Samia Lopa; Robert P Edwards; Lara Lemon; Shu Wang; Sarah E Taylor; Brian Orr; Faina Linkov
Journal:  Cancer Med       Date:  2020-08-19       Impact factor: 4.452

Review 3.  PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.

Authors:  Clifford M Csizmar; Antoine N Saliba; Elizabeth M Swisher; Scott H Kaufmann
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

4.  HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.

Authors:  Hanlin Ma; Gonghua Qi; Fang Han; Wei Lu; Jiali Peng; Rongrong Li; Shi Yan; Cunzhong Yuan; Beihua Kong
Journal:  Cell Death Dis       Date:  2022-03-24       Impact factor: 8.469
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.